This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Targeted Protein Degradation: From Chemical Biology to Drug Discovery

Available via

WEBINAR

Targeted Protein Degradation: From Chemical Biology to Drug Discovery

Tuesday, September 24, 2019, 8:30 AM - 6:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

The majority of disease-causing proteins are not amenable to modulation by conventional pharmacological methods. In recent years an alternative therapeutic strategy known as targeted protein degradation has emerged with the potential to inhibit these “undruggable” proteins. This method utilizes chimeric, tripartite molecules that bind to the protein of interest, thereby promoting its polyubiquitination and subsequent proteosomal degradation. These chimeras can be designed to target a wide range of proteins, and offer the advantage of completely ablating both catalytic and scaffolding functions. Moreover, recent data indicates that these molecules can be developed into effective oral agents, making them therapeutically viable.

This symposium will highlight the latest advances in the field of targeted protein degradation and showcase the benefits of this approach over traditional small molecule inhibitors.

Registration

Member
By 08/21/2019
$90
After 08/21/2019
$130
Nonmember Academia, Faculty, etc.
By 08/21/2019
$180
After 08/21/2019
$260
Nonmember Corporate, Other
By 08/21/2019
$250
After 08/21/2019
$350
Nonmember Not for Profit
By 08/21/2019
$180
After 08/21/2019
$260
Nonmember Student, Undergrad, Grad, Fellow
By 08/21/2019
$100
After 08/21/2019
$145
Member Student, Post-Doc, Fellow
By 08/21/2019
$50
After 08/21/2019
$70
Member
$30
Nonmember Academia, Faculty, etc.
$65
Nonmember Corporate, Other
$85
Nonmember Not for Profit
$65
Nonmember Student, Undergrad, Grad, Fellow
$45
Member Student, Post-Doc, Fellow
$15
Earlybird Registration:
2
days
left
Deadline:
0
days
left

Scientific Organizing Committee

Lynn M. Abell, PhD
Lynn M. Abell, PhD

Agios

Matt Calabrese
Matthew Calabrese, PhD

Pfizer

Eric Fischer, PhD
Eric Fischer, PhD

Dana-Farber Cancer Center

Adam Gilbert
Adam Gilbert, PhD

Pfizer

Matthew Medeiros, PhD
Matthew Medeiros, PhD

Agios

Claire Steppan, PhD
Claire Steppan, PhD

Pfizer

Sara Donnelly, PhD
Sara Donnelly, PhD

The New York Academy of Sciences

Sonya Dougal, PhD
Sonya Dougal, PhD

The New York Academy of Sciences

Keynote Speaker

James Bradner, MD
James Bradner, MD

Novartis Institutes for BioMedical Research

Speakers

Danette Daniels, PhD
Danette Daniels, PhD

Promega

Michael Rape
Michael Rape, PhD

University of California, Berkeley

Paola Castaldi
Paola Castaldi, PhD

AstraZeneca

Shaomeng Wang
Shaomeng Wang, PhD

University of Michigan Medical School

Andreas Martin
Andreas Martin, PhD

University of California, Berkeley

Ingrid Wertz, MD, PhD
Ingrid Wertz, MD, PhD

Genentech

Benjamin Ebert, MD, PhD
Benjamin Ebert, MD, PhD

Dana-Farber Cancer Institute, Harvard Medical School

Philip Chamberlain
Philip Chamberlain, D. Phil

Celgene

Eric Fischer, PhD
Eric Fischer, PhD

Dana-Farber Cancer Center, Harvard Medical School







Tuesday

September 24, 2019

8:30 AM

Breakfast and Registration

9:00 AM

Introduction and Welcome Remarks

Speakers

Sara Donnelly, PhD
The New York Academy of Sciences
Adam Gilbert, PhD
Pfizer

Session 1: Chemical Considerations for Degrader Design

Session Chairperson
Matthew Calabrese, PhD, Pfizer
9:15 AM

Molecular Mechanisms regulating Ubiquitylation

Speaker

Michael Rape, PhD
University of California, Berkeley
9:45 AM

The Ubiquitin System in Disease Pathogenesis

Speaker

Ingrid Wertz, PhD
Genentech
10:15 AM

Networking Coffee Break

10:45 AM

Mechanisms of Action of Cereblon Modulating Agents

Speaker

Philip Chamberlain, D. Phil
Celgene
11:15 AM

Understanding the Eukaryotic 26S Proteosome

Speaker

Andreas Martin, PhD
University of California, Berkeley

Session 2: Data Blitz Talks

Session Chairperson
Matthew Calabrese, PhD, Pfizer
11:45 AM

3X Short Talks Selected from Submitted Abstracts

12:00 PM

Networking Lunch and Poster Session

Speakers

Odd number posters
12:30 PM - 1:00 PM
Even number posters
1:00 PM - 1:30 PM

Session 3: Anatomy of a Chimeric Protein Degrader

Session Chairperson
Lynn Abell, PhD, Agios
1:30 PM

Molecular Principles of Small Molecule Mediated Ubiquitin Ligase Targeting

Speaker

Eric Fischer, PhD
Dana-Farber Cancer Institute
2:00 PM

Characterizing kinetics and functional mechanism of BET protein Protacs

Speaker

Danette Daniels, PhD
Promega

Session 4: Applications of Targeted Protein Degradation

Session Chairperson
Matthew Medeiros, PhD, Agios
2:30 PM

Small-Molecule degraders of Bromodomain and BET proteins

Speaker

Shaomeng Wang, PhD
University of Michigan
3:00 PM

Targeting Lymphoma with a Novel PROTAC

Speaker

Paola Castaldi, PhD
AstraZeneca
3:30 PM

Networking Coffee Break

4:00 PM

Lenalidomide modulates an E3 Ligase to induce Degradation of Key Drivers of Hematologic Malignancies

Speaker

Benjamin Ebert, MD, PhD
Dana-Farber Cancer Institute
4:30 PM

KEYNOTE ADDRESS: Targeted Protein Degradation for Therapeutic Applications

Speaker

James Bradner, MD
Novartis Institutes for Biomedical Research
5:15 PM

Closing Remarks and Poster Prize Presentation

Speaker

Matthew Medeiros, PhD
Agios
5:20 PM

Networking Reception

6:20 PM

Adjourn